LC-MS Analysis Service

LC/MS/MS Method Development & Validation

Development, transfer, and optimization of methods for quantification of drugs in biological matrices
Quick turnaround time to speed up the drug development process

Chemical Analytical Center of Medicilon provides general analysis and purification services for the clients. Our experts have rich experience and proficient skills to solve problems, which are highly appreciated by clients.

General Analytical Chemistry Services

– NMR 1D、2D（H-NMR、C-NMR、P-NMR、F-NMR、HSQC、HMBC、COSY、NOESY, et al）
– LC-MS Analysis
– HPLC Analysis (including ELSD)
– Chiral HPLC Analysis

– General LCMS Testing (ROI、LOD、Cl-、SO42-、mp、HM、Specific Rotation、Water Content, et al）

LC/MS Introduction

LC/MS is short for Liquid Chromatography / Mass Spectrometers.

Liquid Chromatography (LC) is a fundamental separation technique in the life sciences and related fields of chemistry. Unlike gas chromatography, which is unsuitable for nonvolatile and thermally fragile molecules, liquid chromatography can safely separate a very wide range of organic compounds, from small-molecule drug metabolites to peptides and proteins.

Mass Spectrometers (MS) also generate three dimensional data. In addition to signal strength, they generate mass spectral data that can provide valuable information about the molecular weight, structure, identity, quantity and purity of a sample. Mass spectral data add specificity that increases confidence in the results of both qualitative and quantitative analyses.

Why and When to Use LC/MS

The use of LC-MS in many application areas within analytical science continues to grow almost exponentially. Listed below are some pointers as to applicability of both HPLC as a separative technique and MS as a means of detecting analyte species.

Bioanalytical LC-MS method development for quantitative determination of drugs and their metabolites in biological fluids is crucial during drug development. The need for efficiently generated, regulatory compliant bioanalytical data is reliant on fit-for-purpose methods being developed and validated by experienced LC-MS scientists.

Our bioanalysis LC-MS teams are recognized for the ability to efficiently develop and validate routine and non-routine methods in a wide variety of matrices, and to rapidly employ these assays in a GLP-compliant and high throughput sample analysis environment.

lcms testing

Liquid Chromatography Mass Spectrometry System

Below is part of our current services in the Bioanalytical Department:

– Method Transfer and Optimization (LC-MS/MS and HPLC)
– Method Development and Validation (LC-MS/MS and HPLC)
– High Throughput Analysis to Support Discovery TK/PK/PD Studies
– Analytical Support for Clinical Trials
– Support for Preclinical TK/PK Studies
– Pharmacokinetic (PK) Studies
– Metabolite Identification
– Bioequivalence Studies

Contact Us

Email : marketing@medicilon.com
Tel : +86 021 58591500

Tips : Above is part of LC/MS analysis service, LC/MS testing price and LC/MS method development . You can also CONTACT US with any question or enquiry you may have. We will be happy to discuss your needs in detail and design an appropriate plan of action.

LC-MS Method Development and Validation

LC-MS/MS Method Development

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客